Amylyx Pharmaceuticals
AMLX
72 hedge funds and large institutions have $300M invested in Amylyx Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 72 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
980% more call options, than puts
Call options by funds: $5.76M | Put options by funds: $533K
41.48% more ownership
Funds ownership: 0% → 41.48% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$162M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$62.2M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$49.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$33.3M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$22.5M |
Top Sellers
AMLX Hedge Fund Activity: Q1 2022 in Review
72 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2022, worth a combined $300M.
Buyers outnumbered sellers: 72 funds opened new AMLX positions and 0 closed out — a net gain of 72 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $162M.
- 72 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $300M of Amylyx Pharmaceuticals stock for Q1 2022.
- 72 funds opened new Amylyx Pharmaceuticals positions in Q1 2022 and 0 closed out, a net change of +72 holders.
- The largest Amylyx Pharmaceuticals buyer in Q1 2022 was Viking Global Investors, an estimated $162M added.
Based on aggregated 13F filings for Q1 2022.